{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:03:50Z","timestamp":1785765830419,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12471-w","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:41:43Z","timestamp":1785764503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analytical validation of a modified wild-type blocker qpcr assay for the sensitive DNA-based detection of NPM1 type A in acute myeloid leukemia"],"prefix":"10.1007","volume":"53","author":[{"given":"Pejman","family":"Hamedi-Asl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariush","family":"Hamedi-Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaharbano","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davod","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Damerchiloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Manafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Safa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"3","key":"12471_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMoa041974","volume":"352","author":"B Falini","year":"2005","unstructured":"Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254\u2013266","journal-title":"N Engl J Med"},{"issue":"10","key":"12471_CR2","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","volume":"107","author":"C Thiede","year":"2006","unstructured":"Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10):4011\u20134020","journal-title":"Blood"},{"issue":"6","key":"12471_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","volume":"20","author":"P Gorello","year":"2006","unstructured":"Gorello P, Cazzaniga G, Alberti F, Dell\u2019Oro M, Gottardi E, Specchia G et al (2006) Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 20(6):1103\u20131108","journal-title":"Leukemia"},{"issue":"1","key":"12471_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjh.16857","volume":"191","author":"A Bataller","year":"2020","unstructured":"Bataller A, O\u00f1ate G, Diaz-Bey\u00e1 M, Guijarro F, Garrido A, Vives S et al (2020) Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol 191(1):52\u201361","journal-title":"Br J Haematol"},{"issue":"3","key":"12471_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.blre.2017.11.001","volume":"32","author":"P Kunchala","year":"2018","unstructured":"Kunchala P, Kuravi S, Jensen R, McGuirk J, Balusu R (2018) When the good go bad: mutant NPM1 in acute myeloid leukemia. Blood Rev 32(3):167\u2013183","journal-title":"Blood Rev"},{"issue":"7","key":"12471_CR6","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"11","key":"12471_CR7","first-page":"1200","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood J Am Soc Hematol 140(11):1200\u20131228","journal-title":"Blood J Am Soc Hematol"},{"issue":"26","key":"12471_CR8","first-page":"2753","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. J Am Soc Hematol 138(26):2753\u20132767","journal-title":"J Am Soc Hematol"},{"issue":"5","key":"12471_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1507471","volume":"374","author":"A Ivey","year":"2016","unstructured":"Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A et al (2016) Assessment of minimal residual disease in standard-risk AML. N Engl J Med 374(5):422\u2013433","journal-title":"N Engl J Med"},{"issue":"5","key":"12471_CR10","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/sj.leu.2404637","volume":"21","author":"W Chou","year":"2007","unstructured":"Chou W, Tang J, Wu S, Tsay W, Yao M, Huang S et al (2007) Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 21(5):998\u20131004","journal-title":"Leukemia"},{"issue":"1","key":"12471_CR11","first-page":"83","volume":"122","author":"N Shayegi","year":"2013","unstructured":"Shayegi N, Kramer M, Bornh\u00e4user M, Schaich M, Schetelig J, Platzbecker U et al (2013) The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. J Am Soc Hematol 122(1):83\u201392","journal-title":"J Am Soc Hematol"},{"issue":"5","key":"12471_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1600-0609.2011.01673.x","volume":"87","author":"T Kristensen","year":"2011","unstructured":"Kristensen T, M\u00f8ller MB, Friis L, Bergmann OJ, Preiss B (2011) NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 87(5):400\u2013408","journal-title":"Eur J Haematol"},{"issue":"blood","key":"12471_CR13","first-page":"2025031480","volume":"2025","author":"J Cloos","year":"2025","unstructured":"Cloos J, Valk PJ, Thiede C, D\u00f6hner K, Roboz GJ, Wood BL et al (2025) Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Blood J 2025(blood):2025031480","journal-title":"Blood J"},{"issue":"12","key":"12471_CR14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/ajh.21879","volume":"85","author":"D Dvorakova","year":"2010","unstructured":"Dvorakova D, Racil Z, Jeziskova I, Palasek I, Protivankova M, Lengerova M et al (2010) Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations. Am J Hematol 85(12):926\u2013929","journal-title":"Am J Hematol"},{"key":"12471_CR15","doi-asserted-by":"crossref","unstructured":"Racchumi J, Tam W, Kluk MJ (2019) Clinical Laboratory Validation and Implementation of Quantitative, Real-Time PCR-based Monitoring of NPM1 Type A Mutation. medRxiv. :19010124","DOI":"10.1101\/19010124"},{"issue":"26","key":"12471_CR16","first-page":"3041","volume":"136","author":"S Kapp-Schwoerer","year":"2020","unstructured":"Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Kr\u00f6nke J et al (2020) Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09\u201309 trial. Blood. J Am Soc Hematol 136(26):3041\u20133050","journal-title":"J Am Soc Hematol"},{"issue":"8","key":"12471_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.5858\/2010-0490-OAR1","volume":"135","author":"FH Barakat","year":"2011","unstructured":"Barakat FH, Luthra R, Yin CC, Barkoh BA, Hai S, Jamil W et al (2011) Detection of nucleophosmin 1 mutations by quantitative real-time polymerase chain reaction versus capillary electrophoresis: a comparative study. Arch Pathol Lab Med 135(8):994\u20131000","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"12471_CR18","first-page":"1345","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. J Am Soc Hematol 140(12):1345\u20131377","journal-title":"J Am Soc Hematol"},{"issue":"11","key":"12471_CR19","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1038\/s41375-021-01222-4","volume":"35","author":"B Falini","year":"2021","unstructured":"Falini B, Sciabolacci S, Falini L, Brunetti L, Martelli MP (2021) Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. Leukemia 35(11):3113\u20133126","journal-title":"Leukemia"},{"issue":"6","key":"12471_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.5858\/arpa.2021-0601-OA","volume":"147","author":"PR Menegotto","year":"2023","unstructured":"Menegotto PR, Farias MG, Spagnol F, Siebert M, Filippi-Chiela EC, Alegretti AP et al (2023) Comparison of Nonsequencing Techniques for Identification of NPM1 Mutations and Associated Blast Morphology in Patients With Acute Myeloid Leukemia. Arch Pathol Lab Med 147(6):701\u2013709","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"12471_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/gcc.22375","volume":"55","author":"L Pettersson","year":"2016","unstructured":"Pettersson L, Lev\u00e9en P, Axler O, Dvorakova D, Juliusson G, Ehinger M (2016) Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. Genes Chromosom Cancer 55(10):750\u2013766","journal-title":"Genes Chromosom Cancer"},{"issue":"4","key":"12471_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijlh.13608","volume":"43","author":"L Pettersson","year":"2021","unstructured":"Pettersson L, Johansson Alm S, Almstedt A, Chen Y, Orrsj\u00f6 G, Shah-Barkhordar G et al (2021) Comparison of RNA\u2010and DNA\u2010based methods for measurable residual disease analysis in NPM1\u2010mutated acute myeloid leukemia. Int J Lab Hematol 43(4):664\u2013674","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"12471_CR23","first-page":"1275","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 M-C, Buccisano F, Cloos J et al (2018) Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood J Am Soc Hematol 131(12):1275\u20131291","journal-title":"Blood J Am Soc Hematol"},{"issue":"19","key":"12471_CR24","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1182\/blood.2023023096","volume":"143","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD et al (2024) Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 143(19):1931\u20131936","journal-title":"Blood"},{"issue":"45","key":"12471_CR25","doi-asserted-by":"publisher","first-page":"6830","DOI":"10.1038\/sj.onc.1208832","volume":"24","author":"PL Dominguez","year":"2005","unstructured":"Dominguez PL, Kolodney MS (2005) Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. Oncogene 24(45):6830\u20136834","journal-title":"Oncogene"},{"issue":"1","key":"12471_CR26","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1038\/s41598-019-44792-1","volume":"9","author":"X-D Ren","year":"2019","unstructured":"Ren X-D, Liu D-Y, Guo H-Q, Wang L, Zhao N, Su N et al (2019) Sensitive detection of low-abundance in-frame deletions in EGFR exon 19 using novel wild-type blockers in real-time PCR. Sci Rep 9(1):8276","journal-title":"Sci Rep"},{"issue":"12","key":"12471_CR27","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1002\/jmv.25724","volume":"92","author":"N Akuta","year":"2020","unstructured":"Akuta N, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H et al (2020) Detection of TERT promoter mutation in serum cell-free DNA using wild\u2010type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma. J Med Virol 92(12):3604\u20133608","journal-title":"J Med Virol"},{"issue":"6","key":"12471_CR28","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.mcp.2010.07.010","volume":"24","author":"Q Huang","year":"2010","unstructured":"Huang Q, Wang G-Y, Huang J-F, Zhang B, Fu W-L (2010) High sensitive mutation analysis on KRAS gene using LNA\/DNA chimeras as PCR amplification blockers of wild-type alleles. Mol Cell Probes 24(6):376\u2013380","journal-title":"Mol Cell Probes"},{"key":"12471_CR29","volume-title":"EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline\u2014Second Edition. CLSI document EP17-A2","author":"Institute CaLS","year":"2012","unstructured":"Institute CaLS (2012) EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline\u2014Second Edition. CLSI document EP17-A2. Clinical and Laboratory Standards Institute, Wayne, PA"},{"issue":"8","key":"12471_CR30","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/sj.leu.2403846","volume":"19","author":"N Noguera","year":"2005","unstructured":"Noguera N, Ammatuna E, Zangrilli D, Lavorgna S, Divona M, Buccisano F et al (2005) Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia 19(8):1479\u20131482","journal-title":"Leukemia"},{"key":"12471_CR31","doi-asserted-by":"publisher","first-page":"120247","DOI":"10.1016\/j.cca.2025.120247","volume":"572","author":"W Liu","year":"2025","unstructured":"Liu W, Qi X, Wang H, Lin S, Zhang Y, Zhu P et al (2025) Challenges in harmonizing immunoassays: The use of the Bland-Altman based harmonization algorithm. Clin Chim Acta 572:120247","journal-title":"Clin Chim Acta"},{"issue":"1","key":"12471_CR32","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1038\/s41598-024-57016-y","volume":"14","author":"BB Ip","year":"2024","unstructured":"Ip BB, Wong AT, Law JHY, Au CH, Ma SY, Chim JC et al (2024) Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignancies. Sci Rep 14(1):6400","journal-title":"Sci Rep"},{"issue":"5","key":"12471_CR33","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/cam4.2087","volume":"8","author":"S Bernardi","year":"2019","unstructured":"Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D\u2019Adda M et al (2019) Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med 8(5):2041\u20132055","journal-title":"Cancer Med"},{"issue":"4","key":"12471_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jmoldx.2017.03.005","volume":"19","author":"N Mencia-Trinchant","year":"2017","unstructured":"Mencia-Trinchant N, Hu Y, Alas MA, Ali F, Wouters BJ, Lee S et al (2017) Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations. J Mol Diagn 19(4):537\u2013548","journal-title":"J Mol Diagn"},{"issue":"10","key":"12471_CR35","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","volume":"97","author":"M Bill","year":"2018","unstructured":"Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J et al (2018) Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol 97(10):1757\u20131765","journal-title":"Ann Hematol"},{"key":"12471_CR36","doi-asserted-by":"publisher","first-page":"677833","DOI":"10.3389\/fonc.2021.677833","volume":"11","author":"F-J Liu","year":"2021","unstructured":"Liu F-J, Cheng W-Y, Lin X-J, Wang S-Y, Jiang T-Y, Ma T-T et al (2021) Measurable residual disease detected by multiparameter flow cytometry and sequencing improves prediction of relapse and survival in acute myeloid leukemia. Front Oncol 11:677833","journal-title":"Front Oncol"},{"issue":"1","key":"12471_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-019-03861-1","volume":"99","author":"M-G Gao","year":"2020","unstructured":"Gao M-G, Ruan G-R, Chang Y-J, Liu Y-R, Qin Y-Z, Jiang Q et al (2020) The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. Ann Hematol 99(1):73\u201382","journal-title":"Ann Hematol"},{"issue":"1","key":"12471_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-025-01298-6","volume":"15","author":"C Jimenez-Vicente","year":"2025","unstructured":"Jimenez-Vicente C, Cardus A, Casta\u00f1o-Diez S, Ramil G, Garcia-Avila S, Gomez-Perez L et al (2025) Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer J 15(1):94","journal-title":"Blood Cancer J"},{"key":"12471_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cca.2019.03.1618","volume":"494","author":"N Su","year":"2019","unstructured":"Su N, Wei K, Zhao N, Wang L, Duan G-J, Ren X-D et al (2019) Sensitive and selective detections of codon 12 and 13 KRAS mutations in a single tube using modified wild-type blocker. Clin Chim Acta 494:123\u2013131","journal-title":"Clin Chim Acta"},{"issue":"4","key":"12471_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/annonc\/mdz046","volume":"30","author":"B Li","year":"2019","unstructured":"Li B, Janku F, Jung B, Hou C, Madwani K, Alden R et al (2019) Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann Oncol 30(4):597\u2013603","journal-title":"Ann Oncol"},{"key":"12471_CR41","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fonc.2020.00290","volume":"10","author":"C Li","year":"2020","unstructured":"Li C, He Q, Liang H, Cheng B, Li J, Xiong S et al (2020) Diagnostic accuracy of droplet digital PCR and amplification refractory mutation system PCR for detecting EGFR mutation in cell-free DNA of lung cancer: a meta-analysis. Front Oncol 10:290","journal-title":"Front Oncol"},{"key":"12471_CR42","doi-asserted-by":"crossref","unstructured":"Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al (2009) The MIQE Guidelines: M inimum I nformation for Publication of Q uantitative Real-Time PCR E xperiments. Oxford University Press","DOI":"10.1373\/clinchem.2008.112797"},{"issue":"6","key":"12471_CR43","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/clinchem\/hvaf043","volume":"71","author":"SA Bustin","year":"2025","unstructured":"Bustin SA, Ruijter JM, van den Hoff MJ, Kubista M, Pfaffl MW, Shipley GL et al (2025) MIQE 2.0: Revision of the minimum information for publication of quantitative real-time PCR experiments guidelines. Clin Chem 71(6):634\u2013651","journal-title":"Clin Chem"},{"issue":"8","key":"12471_CR44","doi-asserted-by":"publisher","first-page":"e70198","DOI":"10.1002\/hem3.70198","volume":"9","author":"K D\u00f6hner","year":"2025","unstructured":"D\u00f6hner K, D\u00f6hner H, Sp\u00e4th D, Kapp-Schwoerer S, Gilkes A, Thomas I et al (2025) A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1mut AML in MRDneg remission after intensive induction. HemaSphere 9(8):e70198","journal-title":"HemaSphere"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12471-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12471-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12471-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:41:46Z","timestamp":1785764506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12471-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12471"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12471-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known financial interests or personal relationships that could have potentially affected the research reported in this paper.","order":3,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In the preparation of this manuscript, generative AI tools were limited used solely for language editing, including grammar and writing improvements. All scientific content, analyses, and interpretations were created entirely by the authors. Additionally, all figures and tables were generated by the authors without the assistance of AI tools.","order":4,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1325"}}